📣 Attention #Pharma Enthusiasts: Stay tuned for our 'Pharma Weekly Digest' #newsletter today at 1 PM CST. Stay updated with the latest trends and developments in the pharmaceutical industry, presented with a refreshing perspective. 🔗Subscribe 👇🏼 lnkd.in/eWfcdR5K

Big Monday news 📰 : The FDA has approved Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy (exagamglogene autotemcel), the first-ever CRISPR-based gene editing therapy for sickle cell disease.#Pharmaceutical #genetherapy #BigPharma #news

One of the best benches I have seen

Our final newsletter of 2023 is here! #PharmaNews #2023wrapup #biotech pharmaweeklydigest.substack.com/p/the-2023-pha…

🔥How to read MORE & read QUICKER in 2024! Here are some AI tools that will help you find new research papers, understand research results, generate outlines, write quickly and proofread accurately.

Update on Novartis significant licensing deal with Voyager Therapeutics. Novartis has just announced that it’s paying $100 million upfront to Voyager Therapeutics. This collaboration focuses on developing gene therapy candidates, utilizing Voyager's RNA screening platform.

Share your groundbreaking #GreenChemistry #research & submit your abstract for the ACS GCI's Green Chemistry & Engineering Conference held both in-person in Atlanta and virtually. Submit your research by February 12 at brnw.ch/21wFKeR

🔬 Roche and Chinese startup MediLink Therapeutics has struck a remarkable deal ,potentially worth $1 billion, to develop an innovative antibody-drug conjugate (ADC) for cancer treatment. #biotech #pharmanews

Goldman Sachs closes $650M life sciences fund. “We are in a golden-era of innovation in the life sciences, where technological breakthroughs are creating new approaches to diagnosing and treating disease,” endpts.com/goldman-sachs-…

All those pricey Pfizer Inc. acquisitions paid off, as Pfizer Inc. saw 7 of its drugs approved this year, showcasing a successful strategy in drug development. This achievement is part of a broader trend in 2023, where the FDA's novel drug approvals increased by 50%. #biotech #pharmanews

🚨 #Neuralink, led by Elon Musk, faces FDA scrutiny over its California lab practices. Issues include record-keeping and quality control. Inspections were from June 12-22, marking FDA's first for Neuralink. Despite this, they're cleared for human trials.

🔥 We're back! Don't miss this week's "Pharma Weekly News Digest" March 21st - your essential update on the pharmaceutical world. Catch up with us now 👇 pharmaweeklydigest.substack.com/p/pharma-weekl…